Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

AstraZeneca : China Partner Granted Marketing Authorization for Anemia Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/22/2019 | 03:00am EDT

By Oliver Griffin

AstraZeneca PLC (AZN.LN) on Thursday said its partner in China has received marketing authorization for roxadustat for treatment of anemia caused by chronic kidney disease in patients who are non-dialysis dependent.

The pharmaceutical company said FibroGen (China) Medical Technology Development Co., Ltd. was granted marketing authorization by China's National Medical Products Administration and was supported by a Phase III trial.

AstraZeneca said marketing authorization follows the earlier approval in China for roxadustat, which was granted in December, for use by patients who are on dialysis.

The company and its partner expect to launch roxadustat in China during the second half of 2019.

Write to Oliver Griffin at oliver.griffin@dowjones.com; @OliGGriffin

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
08/22ASTRAZENECA : China Partner Granted Marketing Authorization for Anemia Drug
DJ
08/22ASTRAZENECA : to Buy US FDA Priority Review Voucher for $95 Million
DJ
08/22ASTRAZENECA : agrees to buy US FDA Priority Review Voucher from Sobi
PU
08/22ASTRAZENECA : Roxadustat approved in China for the treatment of
PU
08/22ASTRAZENECA : agrees to buy US FDA Priority Review
AQ
08/22ASTRAZENECA : Roxadustat approved in China for the treatment of anaemia in non-d..
AQ
08/21LONDON STOCK EXCHANGE : Oil majors, exporters boost FTSE 100; Fed minutes eyed
RE
08/21AstraZeneca Imfinzi combination fails advanced lung cancer study
RE
08/21ASTRAZENECA : Update on the Phase III NEPTUNE trial of Imfinzi plus tremelimumab..
PU
08/21ASTRAZENECA : Imfinzi, Tremelimumab Combination Didn't Meet Primary Endpoint
DJ
More news
Financials (USD)
Sales 2019 23 979 M
EBIT 2019 6 401 M
Net income 2019 2 292 M
Debt 2019 11 358 M
Yield 2019 3,12%
P/E ratio 2019 50,3x
P/E ratio 2020 36,1x
EV / Sales2019 5,38x
EV / Sales2020 4,90x
Capitalization 118 B
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 89,29  $
Last Close Price 89,72  $
Spread / Highest target 26,6%
Spread / Average Target -0,48%
Spread / Lowest Target -29,4%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Shriti Vadera Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA24.71%117 644
JOHNSON & JOHNSON1.72%347 129
ROCHE HOLDING LTD.12.16%238 668
MERCK AND COMPANY13.49%222 522
NOVARTIS17.97%206 833
PFIZER-20.11%192 868